Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models

Immune checkpoint blockade (ICB) with PD-1 or PD-L1 antibodies has been approved for the treatment of non-small cell lung cancer (NSCLC). However, only a minority of patients respond, and sustained remissions are rare. Both chemotherapy and anti-angiogenic drugs may improve the efficacy of ICB in mo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Transl Med
Main Authors: Martinez-Usatorre, Amaia, Kadioglu, Ece, Boivin, Gael, Cianciaruso, Chiara, Guichard, Alan, Torchia, Bruno, Zangger, Nadine, Nassiri, Sina, Keklikoglou, Ioanna, Schmittnaegel, Martina, Ries, Carola H., Meylan, Etienne, De Palma, Michele
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7612153/
https://ncbi.nlm.nih.gov/pubmed/34380768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.abd1616
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados